Automatic Renewal of Class I and IIa Registrations in Colombia: Timelines Explained
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
On how long the automatic renewal of a Class I/IIa Registro Sanitario actually takes in Colombia, public sources contain two coexisting accounts: Circular Externa 100-0361-16 states that from October 3, 2016, this procedure has been handled through the INVIMA single window, with turnaround cut from about 30 days to about 3 business days; yet in actual practice, companies still report receiving results over a full cycle of about 30 days. GRZAN treats neither figure as the single correct answer — this is a divergence in the practical estimate, not an error committed by one side.
The working conclusion: schedule on the conservative figure of about 30 days, and treat INVIMA’s current window announcements and case-by-case responses as controlling for actual issuance. Planning shipping schedules or tender milestones around 3 business days as if it were a committed deadline is the most common mistake in this procedure. The fee position, by contrast, is consistent: Class I/IIa automatic renewal costs 321.91 UVB under Resolución 2025067543, approximately COP 3,898,330.
2. Legal basis
| Regulation | Number | Publication date | Provisions |
|---|---|---|---|
| Decreto 4725 de 2005 (registration, marketing authorization and health surveillance regime for medical devices) | DECRETO 4725 DE 26 DE DICIEMBRE DE 2005 | December 26, 2005 | Art. 17 (Registro Sanitario Automático) |
| Decreto 582 de 2017 (amending Decreto 4725 de 2005) | Decreto 0582 de 2017 | April 4, 2017 | Art. 32 (automatic renewal for Class I/IIa) |
| Circular Externa 100-0361-16 | Circular Externa 100-0361-16 | 2016 (applicable from October 3, 2016) | Provisions on handling Class I/IIa automatic renewal through the INVIMA single window |
| Ley 962 de 2005 (anti-bureaucracy law) | Ley 962 de 2005 | 2005 | Article 57 (follow-up control within 15 days after issuance) |
| Resolución 2025067543 (2026 fee schedule) | Resolución 2025067543 | December 22, 2025 | Fee schedule: Class I/IIa registration and automatic renewal 321.91 UVB ≈ COP 3,898,330 |
3. Expert insights
1. Both figures come from public sources, and presenting them side by side is what fairness to the reader requires
The claim that automatic renewal takes about 3 business days has a clear source; the observation that it usually takes around a month comes from the rhythm of actual handling. When GRZAN manages a Class I/IIa renewal, it never promises a client either number. Instead, both are presented side by side in the plan, with the note that this reflects a divergence in the practical estimate and that INVIMA’s current window announcements control. That approach looks less certain, but what it avoids is a failed time commitment later — on production planning, shipping, or tender documents — and the cost of that failure far exceeds one extra line of caveat in the plan.
2. Article 32 of Decreto 582 settles whether re-review is needed, not how fast the certificate is issued
The core value of Art. 32 is establishing that Class I/IIa products go through the automatic renewal channel, without the full technical review that Class IIb/III products face. But automatic here refers to the intensity of review, not the speed of issuance: the automatic channel still has to complete the administrative chain of intake, fee verification, system routing and certificate issuance. Reading automatic as instantaneous is the most widespread misunderstanding of this mechanism, and it is precisely the misunderstanding that produces unrealistic downstream schedules.
3. The single window compresses routing steps, not exception handling
What Circular Externa 100-0361-16 describes is the compression of physical routing and manual transfer time achieved by the single window. The moment a case triggers verification — an inconsistent titular record, an unmatched payment, an expired POA — the procedure leaves the pure-routing state and the 3 business days figure no longer applies. GRZAN reads it this way: 3 business days describes the routing time when everything goes right, not the total duration including exception handling. In addition, Article 57 of Ley 962 de 2005 requires INVIMA to conduct a follow-up control within 15 days after issuance; supervision resources are deferred rather than spent up front, which is the institutional reason the front end can be fast.
4. Practical recommendations
- Regulatory affairs leads: schedule external time commitments (shipping, tenders, channel listings) on about 30 days; do not adopt the 3-business-day figure.
- Regulatory affairs leads: before filing, confirm the currently published processing time with the INVIMA single window and keep a record of the confirmation.
- Registration holder (titular): complete a consistency check of the titular name and address (Art. 20) before filing; this is the item that most often triggers exception handling.
- Chinese manufacturers: confirm the POA (Art. 29) is valid on the filing date and throughout the review period; an expired authorization pushes a case out of the fast-routing track.
- Finance teams: pay the fee of 321.91 UVB and confirm the payment can be matched to the application immediately.
- Quality and compliance leads: in line with the 15-day follow-up control under Article 57, prepare supporting documents for the certificate contents in advance.
5. Verification checklist
- □ Both figures — about 3 business days and about 30 days — have been presented side by side, with a note that INVIMA’s current announcements control
- □ The product has been confirmed as Class I/IIa, eligible for the automatic renewal channel of Decreto 582 de 2017, Art. 32
- □ The current processing time has been confirmed with the INVIMA single window and the record retained
- □ The titular name and address have been checked against the information recorded under Art. 20
- □ The POA (Art. 29) has been confirmed valid on the filing date and throughout the review period
- □ The fee of 321.91 UVB has been paid and the payment has been confirmed as matched to the application
Regulatory information verified as of October 29, 2026
All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.
— GRZAN Regulatory Team
GRZAN helps medical device and IVD companies manage the full Colombian post-market compliance cycle — technovigilance and adverse event reporting, recalls and field corrective actions, follow-up control and inspection readiness, renewals and changes to the Registro Sanitario, and ongoing ledger maintenance. For practical support with your Class I/IIa renewals or any other Colombia obligation, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us